ABSTRACT: One-third of infertile couples may have a male factor present. Illicit drug use can be an important cause of male factor infertility and includes use of anabolic-androgenic steroids, marijuana, opioid narcotics, cocaine, and methamphetamines. The use of these illicit drugs is common in the United States, with a yearly prevalence rate for any drug consistently higher in males compared with females. We aim to provide a review of recent literature on the prevalence and effects of illicit drug use on male fertility and to aid health professionals when counseling infertile men whose social history suggests illicit drug use. Anabolic-androgenic steroids, marijuana, cocaine, methamphetamines, and opioid narcotics all negatively impact male fertility, and adverse effects have been reported on the hypothalamic-pituitary-testicular axis, sperm function, and testicular structure. The use of illicit drugs is prevalent in our society and likely adversely impacting the fertility of men who abuse drugs.
''pain-relieving'' medication without a prescription belonging to the respondent, or use that occurred simply for the experience or feeling the drug caused. Pain relievers were defined as medications in the following categories: Darvocet, Darvon, or Tylenol with Codeine; Percocet, Percodan, or Tylox; Vicodin, Lortab, or Lorcet/Lorcet Plus; Codeine; Demerol; Dilaudid; Fioricet; Fiorinal; Hydrocodone; Methadone; Morphine; Oxycontin; Phenaphen with Codeine; Propoxyphene; SK-65; Stadol; Talacen; Talwin; Talwin NX; Tramadol; and Ultram. Cocaine use was defined as use of cocaine in any form, including crack and powder. Methamphetamine use was defined as use of crystal meth, ice, speed, crank, and nonmedical use of Desoxyn or Methederine. This review focuses on use of marijuana, nonmedical use of methamphetamines and Ecstasy (3,4-methylenedioxy-N-methylamphetamine [MDMA] ), nonmedical use of prescription opioid narcotics, cocaine, and AAS, because these illicit drugs can contribute to male factor infertility. AAS use is not collected by the NSDUH survey, and thus AAS use statistics were taken from the 2009 Monitoring the Future (MTF) study. This study is a yearly study of illicit drug use trends among secondary school students, college students, and adults through age 50 years in the United States. This study is conducted annually by the Institute for Social Research at the University of Michigan through grants awarded by the National Institute on Drug Abuse (Johnston et al, 2009) .
Results and Discussion
Marijuana-Marijuana has the highest use rate among all illicit drugs surveyed by the NSDUH in 2009, with 20.1%, 10.6%, and 5.3% of males ages 26-34 years, 35-49 years, and 50 years and older, respectively, reporting use of marijuana in the past year, and 11.6%, 6.2%, and 3.4% of males in these respective age categories reporting use within the past 30 days (Table 1 ). The rate of past year marijuana use between 2008 and 2009 among males 26 years and older increased from 8.8% to 10.0%, respectively (SAMHSA, 2009 (SAMHSA, , 2010 . Impact on Male Fertility-Marijuana, consisting of dried leaves and flowers from the marijuana plant (Cannabis sativa), is smoked to release the psychoactive cannabinoid compound called delta-9-tetrahydrocannabinol (THC). In the 1990s, it was found that cannabinoid compounds are also naturally synthesized by the human body from fatty acid derivatives, termed endogenous cannabinoids or endocannabinoids (Devane et al, 1992; Felder et al, 1992) . The two most wellstudied endocannabinoids are arachidonoylethanolamine, also known as anandamide, and 2-arachidonoylglycerol. Endocannabinoids may modulate several pathophysiologic processes, including neuropathic pain, mood disorders, movement disorders such as Parkinson disease and Huntington disease, disease processes such as cancer, atherosclerosis, and obesity, as well as reproductive functions (Schuel et al, 2002; Pacher (Howlett et al, 2002) , as well as on human testes (Munro et al, 1993; Schuel et al, 2002) and the head and middle pieces of sperm (Rossato et al, 2005) . Human studies consistently conclude that THC negatively affects male reproductive physiology (Table 2) . There are observed disruptions in the hypothalamicpituitary-testicular axis, with marijuana users having decreased levels of luteinizing hormone (LH; Cone et al, 1986; Vescovi et al, 1992) . When investigating testosterone levels, chronic and exclusive marijuana smokers were found to have significantly lower plasma testosterone compared with age-matched controls who had never used marijuana, and the reduction was dose dependent (Kolodny et al, 1974) . More than one-third of the chronic exclusive marijuana smokers studied by Kolodny et al (1974) had oligospermia, likely resulting from decreased LH levels, which reduce testosterone secretion, which in turn reduces spermatogenesis. Activation of the endocannabinoid receptors on sperm by either anandamide or THC has also been reported to reduce sperm motility in a dose-dependent manner and inhibit the capacitationinduced acrosomal reaction (Schuel et al, 2002; Rossato et al, 2005; Whan et al, 2006) . However, Schuel et al (2002) found a biphasic effect at different concentrations of anandamide. Sperm were inhibited at higher levels but hyperactivated at lower levels of anandamide. Reductions in sperm motility may be due to an anandamide-or THCinduced inhibition of sperm mitochondrial activity, which initiates sperm apoptosis (Rossato et al, 2005; Badawy et al, 2009 ). Interestingly, when THC was added to neat sperm, mitochondrial respiration was less affected, suggesting that cells that secrete components of seminal fluid may also secrete unidentified factors that protect against THC's inhibitory actions toward sperm (Badawy et al, 2009 ).
In addition, normal operation of the endocannabinoid signaling systems requires rapid release and rapid removal of endocannabinoids (Piomelli et al, 1998) . THC has a long half-life ranging from 24 to 36 hours because it is lipid soluble, which allows it to enter fatty tissue that then acts as a reservoir to slowly release THC back into the blood. Studies with rats have shown that after THC administration with approximately 0.06% and 0.02% of the administered dose concentrates in brain and testis, respectively (Nahas et al, 2002) . The presence of such doses of THC in the testis may overstimulate endocannabinoid receptors and contribute to alter sperm motility and male infertility. Prescription Opioid Narcotics-Nonmedical use of prescription opioid narcotics, such as Vicodin (hydrocodone/acetaminophen), Darvocet-N (propoxyphene/acetaminophen), and oxycodone have the second highest abuse rate among illicit drugs after marijuana, with 8.3%, 4.8%, and 2.4% of males ages 26-34 years, 35-49 years, and 50 years and older, respectively, reporting nonmedical use of prescription pain medication in the past year, and 3.3%, 2.5%, and 1.0% of men in these respective age groups reporting current nonmedical use of narcotics (Table 1; SAMHSA, 2010) . Impact on Male Fertility-Prescription narcotics result in suppression of the hypothalamic-pituitary axis through opioid-induced inhibition of gonadotropin-releasing hormone (GnRH) pulse patterns, which leads to suppression of LH release and subsequent decrease in testosterone levels and spermatogenesis (Table 3 ). Testosterone deficiency was documented more than three decades ago in patients treated for heroin addiction with methadone (Azizi et al, 1973; Cicero et al, 1975) .
Intravenous administration of various opioid drugs to healthy male participants led to decreases in serum LH due to suppression of LH pulse frequency, with no significant change in follicle-stimulating hormone (FSH) levels (Delitala et al, 1983; Pende et al, 1986) . LH pulse frequency inhibition can be overcome by opioid antagonists, such as naltrexone (Ellingboe et al, 1982; Veldhuis et al, 1984) .
In studies examining endocrine function in men chronically using intrathecal (average dose of morphine, 4.8 mg), oral, and transdermal opioids to control intractable nonmalignant pain, nearly all men reported symptoms of hypogonadism, including decreased libido or impotency and significantly lower testosterone and LH levels, compared with men not receiving opioid treatment (Abs et al, 2000) . Daniell (2002) found that decreases in testosterone and LH did not differ between men consuming different forms of narcotics in comparable doses and were unrelated to the frequency of opioid use and other characteristics such as smoking, alcohol use, height, weight, and body mass index. However, a more recent study suggests that different narcotics may have different impacts on male fertility, because men using buprenorphine, a partial-opioid agonist for opioid dependence, reported significantly higher testosterone levels and lower frequency of sexual dysfunction than men receiving treatment with methadone (Bliesener et al, 2005) . Vuong et al (2010) did an extensive literature review addressing the effects of opioids on the endocrine system and recommend that sex hormone-binding globulin, which is elevated in men taking opioids, as well as free and total testosterone, which are typically decreased, be measured when investigating the prevalence of hypogonadism in men taking opioids. Measuring these parameters would reduce the likelihood that men with total In vitro, human sperm Whan et al, 2006 f testosterone levels at or just above the lower limit of normal would be classified as eugonadal when they are instead hypogonadal (Vuong et al, 2010) . Giving exogenous testosterone is a potential option for countering opioid-induced hypogonadism. Abs et al (2000) found that androgen supplements helped improve sexual function in most patients on chronic intrathecal morphine. In an open-label study of men on chronic opioids with hypogonadism, treatment with testosterone patch therapy at a low dose of 7.5 mg/d resulted in significantly elevated free and total testosterone levels from baseline as well as improved sexual function and mood (Daniell et al, 2006) . However, administration of exogenous testosterone does have the potential to inhibit spermatogenesis. Studies investigating testosterone administration for male contraception have found that exogenous testosterone may cause a negative feedback mechanism on the hypothalamic-pituitary-testicular axis, suppress LH and FSH, deplete intratesticular testosterone, and lead to azoospermia. However, such suppressive effects are dependent on testosterone dose and method of delivery, with transdermal administration alone being the least likely to suppress spermatogenesis (Hair et al, 2001; Gonzalo et al, 2002; Nieschlag, 2010) . It is important to highlight the limitations of the literature, whereby much higher doses of multiple drugs used by abusers make comparisons to medical treatment effects difficult. Cocaine-NSDUH estimates in 2009 report prevalence use of cocaine for males in the age groups 26-34 years, 35-49 years, and 50 years and older at 4.2%, 2.2%, and 1.0% for past year, and 1.5%, 0.9%, and 0.6% for current users, respectively (Table 1; SAMHSA, 2010) . Cocaine use is unique among illicit drugs in that prevalence rates remain steady with age, whereas active use of all other drugs declines throughout the 20s (Johnston et al, 2009 ). Cocaine use began to decline in all age groups in 2008 (Johnston et al, 2009) , and for all age groups, including men and women, the annual number of cocaine initiates declined from 1.0 million in 2002 to 617,000 in 2009. The number of initiates of crack cocaine declined during this period as well, from 337,000 to 94,000. In 2008, the lifetime prevalence of cocaine use among 50-year-olds reached 40% (Johnston et al, 2009 Impact on Male Fertility-Evidence consistently demonstrates the teratogenic effects of cocaine use on fetal development when abused by women during pregnancy, but studies on the impact of cocaine on male fertility are lacking because of the inability to prospectively study effects. Studies are further complicated by probable concurrent use of other illicit substances. However, Bracken et al (1990) reported some interesting findings through interviewing male patients who presented to a Yale infertility clinic. Men with sperm counts less than 20 million per milliliter were two times more likely to have used cocaine within the past 2 years than men who had not used cocaine (Table 4) . Also, men with a 5-year or greater history of cocaine use were two times more likely to have low sperm motility (Bracken et al, 1990) .
In addition to the observations made by Bracken et al (1990) , an understanding of the specific effects of cocaine on male fertility is best estimated through animal studies. Rats that were chronically exposed to cocaine at a level comparable to that of a heavy cocaine user (15 mg/kg body weight) had respective pregnancy rates of 33% and 50% for 100 and 150 days of cocaine exposure, compared with 86% and 100% of controls, respectively, for the same exposure duration (George et al, 1996) . Testicular tissue receptors in rats have also been found to bind cocaine in a saturable and specific manner (Li et al, 1997) . Rodriguez et al (1992) reported that cocaine exposure to rats in low doses (0.5 mg/kg body weight) and high doses (10 mg/kg body weight) resulted in acute negative effects on spermatogenesis, and they also observed that 50%-60% of seminiferous tubules were abnormal, with cellular degeneration, cell sloughing, or abnormal cell structures. Ultrastructural examination of the seminiferous epithelium (spermatogonia, spermatids, and Sertoli cells) revealed vacuoles, abundant lipid droplets, and giant mitochondria (Rodriguez et al, 1992) . Chronic cocaine administration for 90 days to peripubertal rats induced apoptosis in 25% of germinal epithelium of spermatocytes and spermatogonia with DNA displaying a clear ladder pattern (Li et al, 1999a) . Li et al (1999b) also report that blood flow to rat testes is reduced after subcutaneous injections of high-dose cocaine (30 mg/kg body weight), with vasoconstriction found to be most prominent after 15 minutes, persisting up to 60 minutes, and finally restored to baseline by 4.5 hours. They conclude that adverse effects of cocaine on the testes may be in part due to ischemic and postischemic reperfusion injury. Methamphetamines and Ecstasy-Methamphetamine use by men is quite small, with the NSDUH reporting the highest yearly prevalence rate at 1.1% among males in the age group 19-25 years. For males ages 26-34 years, 35-49 years, and 50 years and older, methamphetamine use is 0.7%, 0.9%, and 0.1% for past year use, and 0.4%, 0.5%, and 0.1% for current users of methamphetamine in these age groupings, respectively (Table 1; Johnston et al, 2009 ). The prevalence of Ecstasy (MDMA) use is also highest in the male age group 19-25 years at 5.2%, and it drops considerably for older age groups. Prevalence of Ecstasy use among males ages 26-34 years and 35-49 years for past year use and current use is at 0.5% and 0.1%, respectively, and is Abbreviations: DAMME, D-Ala(2), MePhe(4), Met(0)-01-enkephalin; FSH, follicle-stimulating hormone; LH, luteinizing hormone. nonexistent for men 50 years and older, according to the NSDUH. Impact on Male Fertility-The impact of methamphetamine use on male fertility has not been rigorously explored. Physiologically, amphetamines and MDMA act upon the dopaminergic and serotoninergic systems, influencing the secretion of GnRH (Vitale et al, 1986) . The studies of amphetamines and Ecstasy on male fertility are modeled through animal studies (Table 5) . In vitro and in vivo male rat studies showed that a single injection of amphetamine led to decreased plasma testosterone in a dose-dependent manner (Tsai et al, 1996) . Tsai et al (1996) hypothesize that amphetamines induce an increase in cAMP, which acts through protein kinase A to block transmission of the Ras signaling pathway, an important pathway for transmitting hormones (Marx, 1993) and perhaps also an important pathway for the release of testosterone by Leydig cells. Acute injection of methamphetamine at different doses (5, 10, or 15 mg/kg) induced apoptosis in seminiferous tubules in male mouse testis, and DNA ladders were found with the highest injected doses of 15 mg/kg (Table 5 ; Yamamoto et al, 2002) . Animal studies evaluating the impact of Ecstasy on reproductive neuroendocrine function found MDMA suppressed GnRH and serum testosterone levels, which significantly altered the hypothalamic-pituitary-testicular axis (Dickerson et al, 2008) . The authors report that they administered doses that were relevant to human intake but acknowledge that metabolism and secretion of MDMA vary between species (Easton and Marsden, 2006) . When examining Ecstasy exposure, there was a significantly higher incidence of sperm DNA damage, tubular degeneration, and interstitial edema in testes, although at all doses tested, sperm motility and morphology were not affected (Table 5 ; Barenys et al, 2009 ). Anabolic-Androgenic Steroids-AAS are cholesterol derivatives of testosterone with effects that are both anabolic and androgenic to build lean muscle and enhance masculinization (Kopera, 1985; Bhasin et al, 1996; Sheffield-Moore and Urban, 2004; Pope and Brower, 2009 (Kayser et al, 2007) . It should be emphasized that testosterone, which is available as a prescription medication as well as illicitly, is an AAS (WADA, 2011). Testosterone (T) coupled with epitestosterone (E) have been abused together to disguise T/E ratios in athletic antidoping systems (Saudan et al, 2006) . Elevated T/E ratios have been recognized as a marker of AAS use in athletes. In addition to the athletes who currently are able to dope undetected, the use of performance-enhancing drugs by the general public is a concern, because the typical user of AAS is a ''regular Joe'' who desires a leaner, more muscular physique so he can emulate the media-perpetuated image of masculinity and fitness (Buckley et al, 1988; Parkinson and Evans, 2006; Cohen et al, 2007) . In 2001, the annual prevalence rate of AAS use in high school boys was estimated to be between 8% and 12% but has since declined to an annual prevalence rate of 3% (Johnson et al, 1989; Kanayama et al, 2009b) . In males ages 19-30 years, the annual prevalence rate was 0.7% (Table 1; Johnston et al, 2009 ). However, the lifetime prevalence of AAS use in males is estimated to be between 3.0% and 4.2%, and of concern are case reports of individuals taking AAS who develop depressive withdrawal symptoms after discontinuing AAS, and may develop AAS dependence as a result. Although AAS dependence needs further study, possible hypotheses include psychologic dependence due to body image disorders such as ''muscle dysmorphia'' (Pope et Table 5 . 1997), and physiological dependence similar to opioid dependence, in which AAS potentiates central endogenous opioid activity and withdrawal decreases endogenous opioids, leading to an acute hyperadrenergic syndrome (Kashkin and Kleber, 1989) . Support for the similarity of AAS dependence to opioid dependence is limited in the literature. There are case reports indicating that AAS users are at risk for developing opioid abuse (Tennant et al, 1988) . Kanayama et al (2009b) examined 5 naturalistic-type studies published between 1991 and 2005 that recruited AAS users from gymnasiums or the Internet and attempted to diagnose AAS dependence using the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria of the American Psychiatric Association for substance dependence. They found that 30% of these study participants met DSM-IV criteria for noncyclic dependence, with an average age of onset of dependence in the late 20s (Johnson et al, 1989; Johnston et al, 2009; Kanayama et al, 2009a; Kanayama et al, 2009b) . Kanayama et al (2009a) suggest that there are likely hundreds of thousands of men in their 30s and 40s who began use in high school and are currently dependent on AAS. Many more are likely to experience clinically significant side effects of AAS on fertility (Tennant et al, 1988; Kanayama et al, 2009a) . The understanding of how AAS affects spermatogenesis is complicated by several factors. The method used to obtain information is usually through naturalistic study design, with recruitment of AAS users from gymnasiums or the Internet. This method of recruiting users has inherent selection biases because some users may be more or less likely to disclose their abuse, as well as information bias if users choose to not disclose their use, side effects, and concurrent medications. Many abusers concurrently take antiestrogens, aromatase inhibitors, and human chorionic gonadotropin (hCG) to counteract the adverse effects of AAS and perhaps avert the detection of their use (Kanayama et al, 2009a) .
Even though AAS are Schedule III drugs, they are easy to order over the Internet and easy to selfadminister (Duchaine, 1981; Phillips, 1991) . There is an extreme variability in the types, doses, combinations, and dosing schedules of AAS. Because a direct doseresponse relationship between AAS and muscle growth exists (Bhasin et al, 1996 (Bhasin et al, , 2001 , it is estimated that AAS users often take 600-5000 mg of AAS per week (Parrott et al, 1994; Pope and Katz, 1994; Wilson-Fearon and Parrott, 1999; Fudala et al, 2003; Parkinson and Evans, 2006) . These doses are supraphysiologic in that they are 50-100 times greater than the 40-to 50-mg weekly production of testosterone by normal male testes (Reyes-Fuentes and Veldhuis, 1993) .
Not only do the combinations and types of AAS vary widely, the administration and dosing schedules are just as variable. Typically, two or more types of AAS are taken simultaneously in blocks of 8-16 weeks, and doses are increased and then decreased over the course of the active block, termed ''stacking,'' ''cycling,'' and ''pyramiding,'' respectively (Lukas, 1993; Pope and Katz, 1994; Kanayama et al, 2003) . The goal is to maximize both receptor binding and effect, avoid plateauing, avoid tolerance, and minimize the withdrawal symptoms of fatigue, loss of libido, and depressed mood. Male fertility requires active spermatogenesis, which depends on Leydig cells secreting high levels of endogenous intratesticular testosterone. However, supraphysiologic levels of exogenous AAS actually exert negative feedback on the hypothalamic-pituitary-testicular axis and subsequently reduce FSH, LH, and intratesticular testosterone concentration. These hormonal changes can lead to azoospermia, oligospermia, testicular atrophy, hypogonadotropic hypogonadism, and an increased percentage of morphologically abnormal sperm with amorphous spermatozoa and defects in the head and center pieces (Table 6 ; Schurmeyer et al, 1984; TorresCalleja et al, 2001; Bonetti et al, 2008) .
Usually, spermatogenesis recovers spontaneously within 4-6 months after cessation of AAS (Knuth et al, 1989) , timing that is similar to the recovery of spermatogenesis after the use of pharmacologic levels of testosterone for male contraception (Liu et al, 2006) . However, recovery has been reported to take up to 3 years or longer (Schurmeyer et al, 1984; Turek et al, 1995; Menon, 2003) . Reasons for the extended recovery time are not yet known but are likely due to the wide variety of combinations and types of AAS. Various clinical treatments have been prescribed to reestablish fertility (Gazvani et al, 1997) . Human chorionic gonadotropin can induce spermatogenesis (Martikainen et al, 1986; Gill, 1998) . Tamoxifen, an estrogen receptor blocker, when combined with hCG may alter gonadotropin secretion and improve spermatogenesis, as well as possibly stimulate endogenous testosterone production (Damber et al, 1989) . Clomiphene citrate, a nonsteroidal antiestrogen most often used to initiate ovulation in women, has also been applied in a short course to stimulate normal sex hormone secretion in males by producing a gonadotropin surge (Guay et al, 1995; Tan and Vasudevan, 2003) .
Although the combination of hCG and AAS can maintain spermatogenesis, there can also be a transient impairment on semen quality with abnormal and hypokinetic spermatozoa (Karila et al, 2004) . Many users of AAS are concurrent abusers of hCG, antiestrogens, and aromatase inhibitors in order to counteract the hypogonadotropic hypogonadism and gynecomastia side effects of AAS, and to disguise and prevent detection of AAS abuse (Karila et al, 2004; Basaria, 2010) . Human chorionic gonadotropin and antiestrogens are on WADA's 2009 list of prohibited androgens and androgen modulators. By stimulating endogenous testosterone production and preventing testicular atrophy, hCG and clomifene are concurrently abused by AAS users to avoid detection of exogenous testosterone (Kicman et al, 1990; Hoffman et al, 2009) .
It is difficult to study AAS use and its side effects because of the variable dosing as well as the prevalence of selection and information biases in research design, because most AAS users are recruited from gymnasiums or through the Internet. Clinicians can look for increased libido, virilization, and bulk muscle with atrophic testes as signs of AAS use, but counseling patients can be difficult. Many are fearful to disclose their use of illegal substances and subsequently do not report side effects (Lloyd et al, 1996; Cohen et al, 2007) . Pope et al (2004) interviewed 80 weightlifters, 54% of whom were current AAS users. Although 50% of those using AAS respected physicians with regard to their general medical knowledge, they did not regard the knowledge of the physician regarding AAS as any more reliable than that of their friends, Internet sites, or suppliers of AAS (Pope et al, 2004) . Importantly, 56% of the users had never revealed their AAS use to a physician. Confounding variables such as premorbid attributes of AAS users or concomitant use of other substances also likely influence observed associations in the literature (Kanayama et al, 2009a) . Furthermore, many drug abusers use multiple illicit medications. These medications are used because of their perceived desired effects and to prevent adverse effects caused by the primary abused drug or drugs. This makes interpretation of the literature complicated and often misclassifies adverse effects to one drug that may in fact be due to a coadministered illicit agent.
Conclusion
Illicit drug use is prevalent in our society and may adversely impact male fertility. Use of these illicit substances is often during reproductive years or during critical periods of testicular development. Illicit drug use affects the hormonal axis and causes impairments in semen analysis and functional sperm parameters. There are several notable limitations of our present understanding of the effects of illicit drugs on male fertility. Human studies are limited by their retrospective nature considering prospective studies are challenging to enroll because of the illegal nature of these substances and the fact that their dangerous side effects make human studies unethical. It is difficult to assess and control for multiple illicit drug interactions because many persons taking illicit drugs are often not just taking one type of drug, and interactions with other foods and drugs may affect the metabolism of an illicit drug. For example, AAS, opioids, and cocaine are metabolized via cytochrome p450, and thus inhibitors of this metabolic pathway could prolong the illicit drugs' side effects. Also, interactions can occur as a result of the synthesis of pharmacologically active metabolites, as is the case with the concurrent ingestion of cocaine and alcohol, which produces cocaethylene, a cocainelike compound that enhances the toxicities of these substances (McCance et al, 1995) .
Although estimates have been made regarding the prevalence of illicit drug use, it cannot be determined with accuracy how often illicit drug use leads to impaired spermatogenesis.
When evaluating infertility, it is important for clinicians to inquire about drug use, because use of illicit drugs is often not clearly evident to the clinician. If social history is positive for drug use, the clinician has the opportunity to coordinate treatment to improve reproductive function and initiate lifestyle modifications. The cornerstone to treatment is the cessation of drug use followed by a careful assessment of endocrine status.
